Annovis to Attend the CTAD 2026 with Three Presentations

Annovis Bio (ANVS) will give three presentations at the Clinical Trials on Alzheimer’s Disease conference in Boston on November 16–19, 2026.

Rhea-AI Summary

Annovis Bio (ANVS) will give three presentations at the Clinical Trials on Alzheimer’s Disease conference in Boston on November 16–19, 2026.

The program includes an oral presentation on investigational buntanetap’s mechanism and posters on its pivotal early Alzheimer’s study design and baseline characteristics, and artificial intelligence for predicting drug passage across the blood–brain barrier. Alexander Morin will deliver the oral presentation on November 19; both posters will be displayed November 16–17, with Cheng Fang presenting the trial-design poster. Annovis expects a pivotal data readout in early 2027 and is preparing for a New Drug Application.

Argus 15 min delay 2 alerts

+5.72% vs previous close $1.05 last price 0.9x rel. volume Open Argus

Details

Market move: ANVS +5.72% vs previous close. CTAD 2026 presentations

$0.98 – $1.05 Day Range

$44.81M Mkt Cap at Last Price

On Oct 22, the day this news came out, the latest delayed price for ANVS is 5.72% above the previous close. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $1.05.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

phase 3, proteostasis, blood–brain barrier, new drug application

4 terms

phase 3 medical

"a Phase 3 clinical-stage biotechnology company"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

proteostasis medical

"Restoring proteostasis in Alzheimer's disease"

Proteostasis is the set of cellular systems that make, fold, repair and remove proteins so they work correctly, like a factory’s quality-control and housekeeping teams keeping machines running. It matters to investors because therapies that fix or alter proteostasis can treat diseases caused by damaged or misfolded proteins, driving clinical trial outcomes, regulatory decisions and the commercial value of biotech companies developing those treatments.

blood–brain barrier medical

"Predicting blood–brain barrier permeability"

A protective network of cells and blood vessels that controls which substances in the blood can enter the brain, keeping out many toxins and large molecules while allowing oxygen and nutrients through. For investors, the barrier matters because it determines whether drugs, imaging agents or biologic therapies can reach brain tissue—acting like a security gate that can make development harder, increase costs and regulatory risk, and therefore influence a company’s prospects and valuation.

new drug application regulatory

"prepare for a New Drug Application"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will attend and present at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, happening November 16-19 in Boston, MA.

Presentation details:

1. Title: “Restoring proteostasis in Alzheimer's disease with buntanetap, a small-molecule translational inhibitor of neurotoxic proteins”
    
   • Presenter: Alexander Morin, PhD, Director, Strategic Communications
   • Type: Oral communications
   • Section: Biotech Showcase 7
   • Date & time: November 19, 3:52 p.m. ET
     
     
     
2. Title: “Clinical trial design and baseline characteristics of buntanetap’s pivotal study in treating early Alzheimer’s patients”
   
   
   • Presenter: Cheng Fang, PhD, Chief Scientific Officer
   • Type: Poster presentation (P025)
   • Section: Clinical Trials – Phase IIB & III
   • Poster display: November 16, 2:00 p.m. – November 17, 5:30 p.m. ET
     
     
     
3. Title: “Predicting blood–brain barrier permeability of late-stage small-molecule drug candidates for Alzheimer's disease using artificial intelligence”
   
   
   • Presenter: Alexander Morin, PhD, Director, Strategic Communications
   • Type: Poster presentation (P121)
   • Section: AI-Driven Innovation in Alzheimer’s Therapeutics
   • Poster display: November 16, 2:00 p.m. – November 17, 5:30 p.m. ET
     
     

“Three presentations at CTAD are a testament to our team’s work advancing buntanetap and pushing the Alzheimer’s field forward,” said Maria Maccecchini, PhD, Founder, President and CEO of Annovis. “Our presentations will cover buntanetap’s innovative mechanism of action, our use of AI for evaluating the Alzheimer’s treatment pipeline, and the updates on our pivotal Phase 3 study in early AD. Together, they reflect our progress as we approach a pivotal data readout in early 2027 and prepare for a New Drug Application. We look forward to sharing all this work and connecting with the Alzheimer’s research community.”

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com